Table 1.

Summary of included studies on the magnitude of Option B plus antiretroviral therapy adherence and associated factors, 2019

Author	Year of publication	Country	Study design	sample size	Prevalence (95%CI)
Zacharius et al. [15]	2019	Tanzania	Cross-sectional	305	45.90 (40.31,51.49)
Tsegaye et al. [12]	2016	Ethiopia	Cross-sectional	191	87.43 (82.73,92.14)
Tesfaye et al. [16]	2019	Ethiopia	Cross-sectional	290	81.38 (76.90,85.86)
Shibabaw et al. [23]	2018	Ethiopia	Cross-sectional	41	95.12 (88.53,101.72)
Mihratu et al. [24]	2018	Ethiopia	Cross-sectional	304	79.61 (75.08,84.13)
Lodebo et al. [25]	2017	Ethiopia	Cross-sectional	215	83.72 (78,79,88.66)
Ebuy et al. [13]	2015	Ethiopia	Cross-sectional	277	87.00 (83,04,90.96)
Schnack et al. [26]	2016	Uganda	Cross-sectional	124	95.97 (92.51,99.43)
Okawa et al. [27]	2015	Zambia	Cohort study	321	82.55 (78.40,86.71)
Haas et al. [28]	2016	Malawi	Cohort Study	765	30.07 (26.82,33.31)
Mwalumuli EO [29]	2017	Tanzania	Cross-sectional	338	58.88 (53.63,64,12)
Erlwanger et al. [30]	2017	Zimbabwe	Cohort study	1150	31.91 (29.22,34.61)
Yazine D et al. [31]	2017	Ethiopia	Cross-sectional	269	75.09 (69.92,80.26)
Mihretu T et al. [7]	2019	Ethiopia	Cross-sectional	293	82.59 (78.25,86.94)
Over all with weights from random effect					71.88 (58.54,85.23)